Abstracts tagged "Lupus"

Abstract Number: 1804 • 2015 ACR/ARHP Annual Meeting
Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis
Chi Chiu Mok¹, Kar Li Chan¹, Sau Mei Tse¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To study the association between the metabolic syndrome (MetS) and vascular events, end stage renal failure (ESRF) and mortality in patients with SLEMethods: Patients…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…
Abstract Number: 750 • 2015 ACR/ARHP Annual Meeting
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
Jasvinder A. Singh¹ and Nipam Shah², ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Belimumab is a new approved treatment option for patients with lupus. Our objective was to perform a systematic review of benefits and harms of…
Abstract Number: 992 • 2015 ACR/ARHP Annual Meeting
Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus
Laurence Morel¹, Seung-Chul Choi², Zhiwei Xu², Elisabeth Adkins³, Byron Croker² and Derry Roopenian³, ¹Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³The Jackson Laboratory, Bar Harbor, ME
Background/Purpose: Cellular metabolism controls T cell functions, with TCR-mediated activation enhancing metabolism, and substrate utilization modulating effector functions. Autoreactive CD4 T cells are key effectors…
Abstract Number: 1818 • 2015 ACR/ARHP Annual Meeting
Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Shubhasree Dutta Choudhury¹, Ann Biehl², Maryam Ghaderi-yeganeh³, Zerai Manna⁴ and Sarfaraz Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases2, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institutes of Health Clinical Center Department of Pharmacy, National Institutes of Health, Bethesa, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Immune dysregulation associated with SLE leads to a substantially high background risk of infection. This risk of infection further increases with the use of…
Abstract Number: 2912 • 2015 ACR/ARHP Annual Meeting
Concomitant Kidney Disease in Patients with Lupus Nephritis
Paul Hoover¹, Jose A. Gomez Puerta², Alexander Fine¹, Helmut Rennke³ and Karen H. Costenbader⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology & Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The most common and clinically and histologically best-characterized SLE kidney disease is lupus nephritis (LN). However, other forms of kidney disease can and do…
Abstract Number: 752 • 2015 ACR/ARHP Annual Meeting
A Strong Association Between Gout and Diuretic Use Among Lupus Patients
Eric Wise¹, Emily Lewis², Puja Khanna^2,3, Lili Zhao⁴ and W Joseph McCune⁵, ¹Rhuematology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁴Department of Statistic, University of Michigan, Ann Arbor, MI, ⁵Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: Although gout has historically been thought to be a rare in patients with SLE, recent case series suggest that the incidence of gout in…
Abstract Number: 1085 • 2015 ACR/ARHP Annual Meeting
Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera², Meryl Waldman³, Karran Phillips⁴, Venkataraman Subramaniam⁵, Paul Thompson⁶, Jonathan D. Graf⁷ and Mariana J. Kaplan¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ³NIDDK, National Institutes of Health, Bethesda, MD, ⁴NIDA, National Institutes of Health, Baltimore, MD, ⁵Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, ⁶Biochemistry and Molecular Pharmacology, University of Masshachussetts, Worcester, MA, ⁷Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Levamisole, an anti-helminth drug, has been implicated in cases of drug-induced autoimmunity in humans exposed to adulterated cocaine. Clinical manifestations of levamisole-induced autoimmunity include…
Abstract Number: 1820 • 2015 ACR/ARHP Annual Meeting
Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus
Juanita Romero-Diaz¹, Rocio Moran-Contla², Eric Kimura-Hayama³, Sergio Criales-Vera³, Carlos Núñez-Álvarez², Roberto Ivan Acosta-Hernandez⁴, Mario César Ocampo-Torres⁵ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ²Instituto Nacional de Cs Medicas y Nutricion Salvador Zubiran, Mexico city, Mexico, ³Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁴Society for Worldwide Med Exchange, North Bay Village, FL, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Premature atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the frequency,…
Abstract Number: 2922 • 2015 ACR/ARHP Annual Meeting
HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus
Diana Girnita¹, Paul Brailey² and Alin Girnita³, ¹Division of Immunology, Allergy & Rheumatology, University of Cincinnati Medical Center, Cincinnati, OH, ²Transplant Immunology Division, University of Cincinnati Medical Center -Hoxworth Blood Center, cincinnati, OH, Oman, ³Transplant Immunology Division, University of Cincinnati Academic Health Center, Hoxworth Blood Center, Cincinnati, OH
Background/Purpose: End stage renal disease due to Systemic lupus erytematosus (SLE) is one of the autoimmune disorder leading to renal transplantation. In this single-center study…
Abstract Number: 14 • 2015 ACR/ARHP Annual Meeting
The SLE Susceptibility Gene Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 (NOD-like receptor family pyrin domain containing 3) Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune Complex
Min Sun Shin¹, Youna Kang¹, Elizabeth Wahl¹, Lin Leng¹, Richard Bucala¹ and Insoo Kang², ¹Yale University School of Medicine, New Haven, CT, ²Rheumatology Section, Yale University School of Medicine, New Haven, CT
Background/Purpose: The pathologic hallmarks of systemic lupus erythematosus (SLE or lupus) are altered immune responses to nuclear autoantigens with autoantibody production and subsequent tissue injury.…
Abstract Number: 762 • 2015 ACR/ARHP Annual Meeting
The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators
Arundip Asaduzzaman¹, Babak Noamani², Denisse Bonilla³, Dafna Gladman⁴, Murray Urowitz^5,6, Paul R. Fortin⁷, Carolina Landolt-Marticorena⁸ and Joan E. Wither⁹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Université Laval, CHU de Québec, Québec, QC, Canada, ⁸1E420/Div of Rheumatology, University Health Network, Toronto, ON, Canada, ⁹Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Type I interferon (IFN) is thought to play an important part in the pathophysiology of systemic lupus erythematosus (SLE), and cross-sectional data suggests an…
Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting
Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation
Christian Goess¹, Candace Graff², Ting Ting Zhang², Gregory Preston², Richard McCarthy¹, Matthew Perham¹, Jacqueline Loud¹, Christopher M. Harris¹, Sara Murdock¹, Erik Sampson³, Michael Hoemann⁴, Michael Friedman⁴, Robert Talanian³, Jeremy Edmunds⁴ and Andrew Long¹, ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
Abstract Number: 1825 • 2015 ACR/ARHP Annual Meeting
Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
Indu Poornima¹, Kelly J. Shields², Susan Manzi³, Rosalind Ramsey-Goldman⁴, Carrie Richardson⁵, Lewis Kuller⁶, George Kondos⁷, James Carr⁵, Craig Langman⁵, Heather Price⁵, Daniel Edmundowicz⁸ and Rachel Mackey⁹, ¹Division of Cardiology, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Allegheny Singer Research Institute, Pittsburgh, PA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Evanston, IL, ⁶Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁷University of Illinois in Chicago, Chicago, IL, ⁸Cardiology, Temple University School of Medicine, Philadelphia, PA, ⁹Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In the general population, we and others have reported that higher osteoprotegerin (OPG), a protein involved in bone remodeling, is associated with higher levels…
Abstract Number: 2926 • 2015 ACR/ARHP Annual Meeting
Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Min Kyung Chung², Ji Hun Kim², Jung Hee Koh³, Seung Min Jung⁴, Jennifer Lee², Seung-Ki Kwok⁵, Ji Hyeon Ju⁶, Kyung-Su Park⁷ and Sung-Hwan Park², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a safe and effective treatment for systemic lupus erythematosus (SLE), and its blood concentration is known to be closely related to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.